First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of ARV-102, a PROTAC LRRK2 degrader, in healthy volunteers

Authors: Sergey Aksenov, Ana LC Zaninotto, Thomas Storz, Y. Folami, C. Lubeski, Marsha MacDougall, Adam W. Hendricson, Sandra G. P. J. Korsten, Philip H. C. Kremer, Angela M. Cacace

Journal: Parkinsonism & Related Disorders

Publication year: 2025

DOI: 10.1016/j.parkreldis.2025.107624

View this paper on Academic Now